# Effect of Ocrelizumab on Brain Innate Immune Microglial Cells Activation in MS Using PET-MRI With 18F-DPA714

> **NCT03691077** · PHASE3 · UNKNOWN · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 51 (estimated)

## Conditions studied

- Multiple Sclerosis
- Relapse
- Primary Progressive Multiple Sclerosis

## Interventions

- **DRUG:** Ocrelizumab

## Key facts

- **NCT ID:** NCT03691077
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-11-11
- **Primary completion:** 2024-05
- **Final completion:** 2024-09
- **Target enrollment:** 51 (ESTIMATED)
- **Last updated:** 2023-09-06

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03691077

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03691077, "Effect of Ocrelizumab on Brain Innate Immune Microglial Cells Activation in MS Using PET-MRI With 18F-DPA714". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03691077. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*